Recent Company News

• 08:39 AM ET Oct 09, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:18 PM ET Oct 08, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight (0.62%); Hang Seng Futures (1.53%)

• 08:03 PM ET Oct 08, 2026
  

  Innovent Biologics's Sycume meets primary endpoint in phase III RESTORE-3 study for inactive thyroid eye disease (HK$92.60, 0.00)

• 10:59 AM ET Oct 06, 2026
  

  StreetAccount Sector Summary - China Healthcare September Recap

• 09:20 PM ET Sep 29, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight (1.55%); Hang Seng Futures (0.51%)

• 03:57 AM ET Sep 29, 2026
  

  Innovent Biologics presents updated phase 1 data for IBI3003 for R/R MM at International Myeloma Society Annual Meeting (HK$95.85, -0.30)

• 09:23 PM ET Sep 28, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight +1.12%; Hang Seng Futures +0.11%

• 06:29 AM ET Sep 28, 2026
  

  NMPA approves Innovent Biologics' Jaypirca for CLL/SLL across all lines of therapy (HK$96.15, 0.00)

• 09:19 PM ET Sep 27, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight (0.64%); Hang Seng Futures (0.86%)

• 08:03 PM ET Sep 27, 2026
  

  Innovent Biologics expands global Phase 3 MarsLight-11 trial (HK$99.70, 0.00)